Electronic medical records company Allscripts took a $200 million (or 10%) stake in drug discovery company NantHealth to strengthen their alliance focused on personalized medicine in the cancer treatment arena.
Qiagen relies on companion diagnostics to keep its engine running, and the company is looking to gain some ground in the field through a new joint venture with German molecular diagnostics outfit Biotype Diagnostic.
Celgene is paying about $1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $150 million upfront and paying $93 a share--a huge premium--to snap up 9.1 million shares of Juno Therapeutics, inking a collaboration to develop and commercialize new oncology therapies.
Australia's CSL unveiled Phase III trial results for hemophilia B candidate rIX-FP that met the primary endpoint and separately noted it bought exclusive rights to commercialize flu treatment Rapivab from BioCryst Pharmaceuticals last week. The note highlighted the growing reach of the biopharma in a core blood products business and in vaccines following its purchase of a Novartis unit last year.
BlackBerry has been working hard to expand its presence in healthcare since losing its share of the smartphone market, scouting out opportunities to diversify its offerings as it makes a name for itself in the industry. Now, the company is taking its healthcare aspirations one step forward, planning to design a bacteria-free smartphone device geared toward hospitals.
3-D printer Materialise and Beijing-based cardiovascular specialist Fuwai Hospital have partnered to open a multidisciplinary 3-D printing center for use in clinical planning. Medical uses are a large and fast growing segment for Materialise, which has done several high-profile deals targeting the industry.
China-based Ascletis Pharmaceuticals has notched up a first with plans for Phase III trials of danoprevir (ASC08) and ASC16 (PPI-668) to treat chronic hepatitis C in China and Taiwan. If successful, the trials could represent a milestone that could reach an estimated patient population of 30 million to 40 million, the highest worldwide.
Google is teaming up with The Broad Institute of MIT and Harvard to create new ways of sharing genomic data and reduce barriers associated with storing and processing genetic information.
Google Genomics is partnering with the Broad Institute to address some of the infrastructural issues around storing huge data sets as well as developing new tools needed to analyze the data and come up with some new directions on human health and treatments.
Qiagen will combine its expertise in assays and biomarker panels with Hitachi's knowledge of instrumentation and manufacturing to advance research-based and clinical molecular testing via a strategic collaboration.